. The treatment over a 1-year period resulted in a significant and sustainable improvement in exercise capacity in this patient population.2
CSL Vifor has granted American Regent, Inc., a Daiichi Sankyo Group company, an exclusive right to develop, manufacture and market Injectafer® in the United States. Please also visit https://americanregent.com/news/ to access the public announcement from American Regent, which does not form a part of this release.
*The New York Heart Association Functional Classification is used by Healthcare Professionals to classify patients'
based on the severity of their symptoms. Patients who have a slight or marked limitation of their physical activity due to
, palpitation and/or
are considered to have class II or class III
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in
and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Injectafer / Ferinject
Injectafer® / Ferinject® (ferric carboxymaltose) is an i.v. iron therapy with market authorization in 85 countries by May 2023. It has a track record of delivering significant value to patients and healthcare systems which is based on extensive clinical data and more than 25 million patient years of exposure. Injectafer is the most extensively studied IV iron.4,5
in adult and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney disease.1